ABSTRACT
Methods and results
We evaluated clinical outcome up to 6 years after PCI in all patients undergoing a PCI procedure for different indications in Sweden between January 2006 and December 2010. Patients were included only once and we adjusted for differences in baseline and procedural characteristics. A total of 70,479 patients were treated for stable CAD (21.0%), unstable angina (11.0%), non ST-elevation myocardial infarction (NSTEMI) (36.6%) and ST elevation myocardial infarction (STEMI) (31.4%). Risk factors and medical history differed between the indications. Mortality was higher in STEMI patients at 1 year after PCI (9.6%) compared to NSTEMI (4.7%), unstable angina (2.2%) and stable CAD (2.0%). On long term after PCI, the adjusted mortality risk and the risk of myocardial infarction were comparable between NSTEMI and STEMI patients and lower in patients with unstable angina and stable CAD. The adjusted risk of stent thrombosis and heart failure was highest in STEMI patients.
Conclusion
Short and long term mortality after PCI differs considerably between different indications. For reduction of mortality in patients with acute coronary syndromes undergoing PCI, therapies and strategies to reduce stent thrombosis and development of heart failure appear to be most important.
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INTRODUCTION
Treatment with percutaneous coronary intervention (PCI) improves outcome in patients with ST-elevation myocardial infarction (STEMI) and in patients presenting in the acute phase of non-ST elevation myocardial infarction (NSTEMI). [1] [2] [3] In patients with stable coronary artery disease (CAD), PCI has not been proven to result in an improved prognosis compared to optimal medical therapy, and is mainly performed to reduce symptoms. 4 In the past decade, differences in mortality have been widely investigated in patients with different presentations of CAD, especially NSTEMI and STEMI. However, the results are inconsistent on short-and long term. In the first year after myocardial infarction, studies have reported both a higher, [5] [6] [7] comparable [8] [9] [10] [11] and lower 12 mortality in STEMI patients compared to NSTEMI patients. On the long term, some studies have reported a comparable mortality risk in NSTEMI and STEMI patients, 6, 7, 13 while others observed a higher mortality risk among NSTEMI patients. 12, 14 In these studies, various proportions of patients have been treated with PCI as reperfusion and revascularization strategy and the studied patient populations have been selected. Therefore, it may be questionable if the previous studies reflect current real world clinical practice.
The aim of this study was to evaluate clinical outcome after PCI over the whole spectrum of CAD in a nation-wide PCI population. We investigated early and late mortality after PCI, and other clinical events that could contribute to the understanding of differences in mortality at short-and long term follow-up.
METHODS
Selection of patients
In the present study, we included all patients with CAD undergoing a PCI procedure in Sweden between January 2006 and December 2010. From 2006 and onward, there were nearly no missing data and the proportions of indications of PCI were relatively stable over time. All patients were included only once in the analyses. Patients without Swedish personal identification number, necessary for merging with other registries were excluded. In addition, patients with unstable CAD were excluded when there was uncertainty about the presence of myocardial damage based on biomarkers.
SCAAR data
The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) documents all coronary angiography-and PCI procedures performed at any of the 30 hospitals with a catheterization laboratory in Sweden from 1989 and onward. SCAAR is part of the nation-wide Swedish Web-system for Enhancement and Development of Evidencebased care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. Data are prospectively collected following the registration standards for clinical practice, and data are reported in a web-based interface. 15, 16 Collection of data on baseline, angiographic and procedural characteristics is initiated at the catheterization laboratory by the treating physician. The long term follow-up data were available by merging data from national patient registers with SCAAR on the basis of the unique personal identification number that all Swedish citizens have. Vital status 37 and date of death were obtained from the Swedish National Population Registry until December 31, 2011. Follow-up concerning hospitalizations for myocardial infarction (ICD 10 th revision, codes I21 and I22) and heart failure (ICD 10 th revision, codes I50, I97, I13.0, I13.2, K76.1) was derived from the National Patient Register, and was available until December, 31 2010. Information regarding stent thrombosis and restenosis is registered in SCAAR itself at any coronary angiography performed in Sweden, irrespective of where in the country the initial PCI was performed, and followup was available until December 31, 2011. The merging with SCAAR was performed by the Epidemiologic Center of the Swedish National Board of Health and Welfare, and was approved by the ethics committee of Uppsala University.
Indications of PCI
In SCAAR, the indication for PCI in patients with CAD is registered as stable CAD, unstable CAD, or STEMI. Stable CAD is defined as symptoms of chest pain during exercise relieved by rest or nitroglycerin, described as definite angina or probable angina according to the Coronary Artery Surgery Study (CASS) classification. 17 Unstable CAD is defined as typical symptoms of chest pain progressive during the last 4 weeks, occurring at rest or less responsive to nitroglycerine; new onset of symptoms during the last 4 weeks; or typical symptoms during the initial 4 weeks after myocardial infarction. In this study, patients classified as unstable CAD were divided into unstable angina and non ST-elevation myocardial infarction (NSTEMI) based on the elevation of biomarkers of myocardial damage (CK-MB or troponin-T level ≥2 times upper limit of the normal range) before PCI. STEMI was defined as clinical suspicion of ongoing 38 
Clinical outcomes
We investigated clinical outcome after PCI for the different indications during the first year after PCI and at the long term follow-up. The pre-specified primary outcome was all-cause mortality. Secondary outcomes were myocardial infarction, stent thrombosis, restenosis and admission for heart failure. For all secondary outcomes, we analyzed the first-time admission for the event after the index-PCI. The first-time admission for myocardial infarction ≥2 days after the index-PCI was defined as new myocardial infarction. Stent thrombosis and restenosis were assessed by the operator during coronary angiography at any subsequent angiography or PCI procedure. Stent thrombosis was confirmed on the coronary angiogram with angiographical signs of a thrombus or an occlusion in the stent combined with an acute clinical presentation. Restenosis was defined on the coronary angiogram as a diameter reduction of >50% in the index-stent or balloon on any subsequent coronary angiography performed on a clinical indication.
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Statistical analysis
The patients were divided in four groups based on the indication for PCI. Categorical variables are presented as frequency values and proportions and differences between the indications were compared using the chi-square test. Continuous variables with a normal distribution are presented as mean ± standard deviation (SD). Differences in continuous variables were evaluated using 1-way analysis of variance. The cumulative incidence of mortality, myocardial infarction, stent thrombosis, restenosis and heart failure was presented by Kaplan Meier event curves for the different indications of PCI. We performed landmark analyses at 1 year after PCI to provide a separate insight in the early and late risks of events. Cox regression analyses were performed to adjust for covariates. We adjusted for all observed significant differences in baseline, angiographic and procedural characteristics (Table 1, 2) , including the year of the PCI procedure and hospital. For the end points mortality, myocardial infarction, restenosis and heart failure we did not adjust for mean total stent length and mean stent diameter as not all patients received a stent. The adjusted hazard ratios are reported with corresponding 95% confidence intervals. STEMI patients were defined as reference category to make it possible to compare the risks of events between NSTEMI and STEMI patients. The log minus log test and the scaled Schoenfeld residuals were evaluated to test the proportional hazard assumption. For all analyses, 2-sided p values <0.05 were defined as significant. Statistical analyses were performed using SPSS 
Baseline and procedural characteristics
The mean age of the PCI patients was 66.9 (SD±11.1) years, which was slightly different between the indications ( 
41
The proportion of drug-eluting stent (DES) use differed between the indications for PCI (Table 2) . 
Mortality
The median time to mortality or end of follow-up was 3.25 years (interquartile range 1.96-4.62). During the 6 year follow-up, there was a lower cumulative incidence of mortality in stable CAD, unstable angina and NSTEMI patients compared to STEMI patients ( Figure 2A) . Mortality rates at 1 year after PCI were 2.0% (N = 301) in stable CAD, 2.2% (N = 168) in unstable angina, 4.7% (N = 1209) in NSTEMI and 9.6% (N = 2119) in STEMI patients. After adjustment for differences in baseline and procedural characteristics there was a lower risk of mortality in patients with stable CAD, unstable angina, and NSTEMI patients compared to STEMI patients in the first year after PCI (Table 3 , Figure 2B ). Between 1-6 years after PCI, the risk of mortality was lower in patients with stable CAD and unstable angina as compared to STEMI patients, but there was no difference between NSTEMI and STEMI patients. 
Myocardial infarction
During the 5 year follow-up, the cumulative incidence of myocardial infarction was higher in NSTEMI patients compared to STEMI patients, and was lower in stable CAD and unstable angina compared to STEMI patients ( Figure 3A ). In the first year after PCI, myocardial infarction occurred in 4.1% (N = 496) of patients with stable CAD, in 5.5% (N = 353) of patients with unstable angina, in 11.0% (N = 2249) of patients with NSTEMI and in 10.3% (N = 1828) of patients with STEMI. The adjusted risk of myocardial infarction was lower in patients with stable CAD and unstable angina compared to STEMI patients, and did not differ between NSTEMI and STEMI patients during the first year and between 1-5 years after PCI (Table 3 , Figure 3B ). 
Stent thrombosis
During the total follow-up of 6 years, the cumulative incidence of stent thrombosis was lower in patients with stable CAD, unstable angina and NSTEMI compared to patients with STEMI ( Figure 4A ). In the first year after PCI, stent thrombosis occurred in 0.7% (N = 96) of patients with stable CAD, in 0.8% (N = 61) with unstable angina, in 1.3% (N = 305) with NSTEMI and in 1.4% (N = 290) with STEMI. The adjusted risk of stent thrombosis was lower for the other indications of PCI compared to STEMI in the first year after PCI and in the period between 1-6 years after PCI (Table 3, Figure 4B ). 
Restenosis
During the total follow-up of 6 years, the cumulative incidence of restenosis was higher in patients with stable CAD, unstable angina and NSTEMI compared to patients with STEMI ( Figure 5A ). In the first year after PCI, restenosis occurred in 6.3% (N = 939) of patients with stable CAD, in 7.4% (N = 580) of patients with unstable angina, in 5.6% (N = 1449) of patients with NSTEMI and in 4.6% (N = 1014) of patients with STEMI ( Figure 5A ). The adjusted risk of restenosis was higher in patients with stable CAD, unstable angina and NSTEMI compared to STEMI in the first year after PCI (Table 3 , Figure 5B ). There was no difference in the risk of restenosis for the different indications between 1-6 years after PCI.
Heart failure
During the 5 year follow-up, the cumulative incidence of heart failure was lower in patients with stable CAD and unstable angina compared to patients with STEMI, and did not differ between patients with NSTEMI and STEMI ( Figure 6A ). During the first year after PCI, heart failure occurred in 5.0% (N = 608) of patients with stable CAD, in 5.5% (N = 354) with unstable angina, in 8.5% (N = 1735) with NSTEMI and in 9.4% (N = 1676) with STEMI. The adjusted risk of heart failure was lower for all other indications compared to STEMI in the first year after PCI (Table 3, Figure 6B ). Between 1-5 years after PCI, the risk of heart failure was lower in patients with stable CAD and unstable angina compared to STEMI, and did not differ between NSTEMI and STEMI patients.
DISCUSSION
We evaluated clinical outcome for the different indications of PCI in a contemporary population at short-and long term follow-up. Baseline characteristics differed substantially between the indications of PCI, as well as treatment strategy. During the first year after PCI mortality risk was highest in patients with STEMI compared to NSTEMI, unstable angina and stable CAD. Between 1 and 6 years after PCI, the adjusted mortality risk was comparable in STEMI and NSTEMI patients but higher than in unstable angina and stable CAD patients. The adjusted risk of stent thrombosis and heart failure was highest in STEMI patients compared to the other indications.
Clinical outcome after PCI have been widely investigated in patients with NSTEMI and STEMI. Previous studies often report that NSTEMI patients have an equal or higher mortality risk compared to STEMI patients at the long term after PCI. 6, 7, [12] [13] [14] However, comparisons are difficult as studies differ in evaluated time intervals, performance of landmark analyses and adjustments for covariates. Differences between our findings and previous studies are most likely influenced by patient selection. In addition, years of inclusion of patients, total number of patients included and the adjustment for many differences in baseline and procedural findings could have contributed. The complete registration of all consecutive PCI procedures in Sweden made it possible to analyze an unselected contemporary nation-wide population.
Baseline characteristics and risks differed between the indications of PCI. Although the mean age did not substantially differ between the indications, the proportion of patients 48 ≥80 years was twice as high in NSTEMI and STEMI patients compared to patients with stable CAD and unstable angina. In addition, there was a great difference in the proportion of smokers, ranging from 10.6% in stable CAD to 28.0% in STEMI patients. NSTEMI patients presented more often with risk factors for CAD and a prior myocardial infarction or PCI compared to STEMI patients. This may indicate that NSTEMI patients have more extensive CAD than STEMI patients, as previous studies suggested. 5, 14 However, the number of diseased vessels did not substantially differ between NSTEMI and STEMI patients. Previous contacts with health care providers could have contributed to the higher incidence of risk factors in NSTEMI patients, while STEMI patients may not have been aware of their risks until admission for myocardial infarction.
We did not observe a difference in the adjusted risk of mortality between NSTEMI and STEMI patients 1-6 years after PCI. However, there was a substantial difference in mortality risk between patients with and without elevated biomarkers of myocardial damage at short-and long term follow-up. The great difference in mortality, especially between unstable angina and NSTEMI patients confirms that myocardial damage is an important predictor of mortality, as previously reported at 6 months. 19 Furthermore, the adjusted risk of heart failure was comparable in NSTEMI and STEMI patients and was lower in patients with unstable angina or stable CAD on long term, distinguishing the risk between patients with and without myocardial damage.
The adjusted risk of myocardial infarction was nearly twice as high in NSTEMI and STEMI patients compared to patients with stable CAD and unstable angina in the first year after PCI, and was also higher at the long term. We did not observe a difference in the risk of myocardial infarction between NSTEMI and STEMI patients. Firstgeneration DES have been associated with an increased long-term risk of stent thrombosis. Despite lower proportions of DES use in STEMI patients, stent thrombosis risk was higher in STEMI patients compared to all other indications, even on long term. The activated coagulation may play a role, present in STEMI patients until months after an acute event. In addition, undersizing of stents may contribute, due to vasoconstriction or mural thrombus in the acute phase of myocardial infarction. The introduction of more potent and consistent platelet inhibitors, as ticagrelor and prasugrel, may reduce the risk of stent thrombosis in clinical practice. 20 During the first year after PCI the risk of restenosis showed an opposite risk pattern compared to stent thrombosis, with the lowest rates of restenosis in patients with acute coronary syndromes, despite the lower proportion of DES use. The presence of myocardial damage in these patients could have contributed to a lower demand of blood flow to an area with infarcted myocardium, causing less symptoms of ischemia and less re-angiographies. After the first year after PCI, no differences in the risk of restenosis were found.
Limitations
Like in all observational studies of registry data, there are several limitations that need to be addressed. Data from observational registries typically have lower quality and there are more often missing data as compared to randomized clinical trials. In SCAAR, 49 the completeness of the data have substantially improved over time, with nearly no missing data after 2006. Furthermore, baseline and procedural characteristics differed between the indications of PCI, and greatly influenced the clinical outcomes. Therefore, we adjusted for all measured covariates.
Conclusions
In this contemporary, unselected population, mortality at 1 year after PCI was higher in STEMI patients compared to other indications. After the first year after PCI, we observed a substantial difference in the adjusted risk of mortality between patients with and without myocardial damage. NSTEMI and STEMI patients had a higher risk of myocardial infarction and heart failure compared to patients with unstable angina and stable CAD on short-and long-term. The risk of stent thrombosis was highest in STEMI patients, even at the long term. This suggests that improvements in therapy are needed in the acute phase as well as on long-term. Specifically, therapies and strategies to reduce stent thrombosis and development of heart failure appear to be most important for the reduction of mortality in patients with acute coronary syndromes undergoing PCI.
